

To receive a CME certificate for this program please answer the post test questions and email to jjoyce@specialtylabs.com or fax back to 661.799.5263 Attn John Joyce

Warfarin Dosing using Genetic Information: A Model for Hospital Policy Development
Jean Lopategui, MD

Participant Name

Phone Number

Email:

Post Test Questions

1. The two genes associated with warfarin dosing are:
 - A. CYP2C9 & VKORC1
 - B. CFTR & BCR/ABL
 - C. CYP2D6 & UGT1A1
 - D. JAK2 V617F & TPMT

2. Warfarin is:
 - A. a safe drug at any dose
 - B. responsible for 87,000 major bleeding events per year
 - C. not very widely prescribed
 - D. not a concern of the FDA

3. The FDA has changed the medical product label for warfarin:
 - A. without evidence of a safety concern
 - B. because warfarin is an old drug
 - C. as part of the FDA Critical Path Initiative
 - D. All of the above

4. A hospital-wide warfarin dosing policy should be developed by:
 - A. Pharmacy
 - B. Cardiology and other medical staff
 - C. Laboratory
 - D. All of the above